Foundayo vs Tirzepatide: An Oral GLP-1 Pill Against a Weekly Dual Agonist
Foundayo vs tirzepatide is now the most common question in weight management visits, and the two drugs have never been tested against each other. In separate 72-week trials, the highest orforglipron dose produced an 11.2 percent mean weight reduction…
Cannabis, CBD, and Insomnia: What Causes Sleeplessness and What the Evidence Supports
CBD for insomnia is sold with far more confidence than the trial evidence supports, and a physician should say so plainly. Controlled studies of cannabidiol, THC, and cannabinol in diagnosed insomnia have mostly missed their primary endpoints while…
Skin and Injection Site Reactions on GLP-1 Medications: How Common, Which Drug, and What to Do About It
GLP-1 injection site reactions and skin complaints made up 31 percent of 442,567 adverse event reports across six agents in a 2026 review, with pooled randomized trials showing a 3.55-fold higher risk than comparators. Almost all of these reactions are…
Does Cannabis Let People Take Fewer Opioids? The Trials and the Surveys Disagree, and the Trials Are Better
Cannabis opioid sparing is the most common reason patients give for wanting medical cannabis, and it is the claim with the widest gap between belief and randomized evidence. Pooled trials in acute and cancer pain show no reduction in opioid dose, a…
Core Symptoms, or Everything Around Them? What Cannabis Trials in Autism Have Actually Measured
Cannabis for autism core symptoms is a claim that depends entirely on which instrument a trial used, and the randomized evidence separates cleanly along that line. Global clinical severity, anxiety, mood and caregiver burden have improved against…
How Long Does Cannabis Impairment Last? The Question the FAA Just Asked the National Academies to Answer
Cannabis impairment duration is the specific scientific question underneath the FAA's request for expert input on fitness for duty. Meta-analytic evidence supports a recovery window of about five to seven hours after inhaled THC, with oral routes longer…
CBD and Prostate Cancer: Cell and Mouse Studies Show Activity, and the One Human Trial Tested Only Safety
Research on CBD and prostate cancer is preclinical: cannabidiol induces apoptosis in PC3 cells and slowed tumor growth in mice, reported by two independent laboratories. The only completed human study gave pharmaceutical cannabidiol to 21 men with rising…
PP-01 for Cannabis Withdrawal: What a 14-Person Trial Found
PP-01 for cannabis withdrawal was associated with improved symptom ratings, sleep, and craving in a randomized 14-person crossover trial. The study lasted five nights in an inpatient setting and reported mild adverse events with no serious adverse…
Medical Cannabis for Inflammatory Arthritis Pain: What a 24-Month Registry Found
medical cannabis inflammatory arthritis: A prospective UK registry case series followed 192 adults prescribed cannabis-based medicinal products for inflammatory arthritis pain. Patient-reported pain, sleep, and quality-of-life measures improved from…
Adolescent Cannabis Quit Attempts Lag Behind Tobacco
Adolescent cannabis quit attempts were reported by 38.7% of California students who used cannabis. Quit attempts were more common among nicotine-vape and cigarette users in the same survey. Perceived harm was associated with quit attempts, but the study…
